Partnerships

 

 

This conference provides a space for those directly involved in cementing the details of partnerships with big pharma, biotechs, academia and non-profit organisations to share their case studies and gain insight into best practice. If you are looking for potential partnerships and collaborations, makes sure you participate in this conference to meet new vaccine biotechs showcasing their technology and pipeline.

 

 

Who Attends

 

• Pharma
• Biotech
• National and International Government
• Non-Profit Organizations
• Academics and Research Institutions
• Consultants
• Venture capitalists
• Investors
• Lawyers

 

Job Titles

 

• CEO / CSO / COO
• Head of Corporate Development
• Head of Licensing/Out-Licensing
• Head of Pipeline Management
• Head of Outsourcing
• Head of Strategy
• Head of Alliancing/alliance management
• Head of Legal/Contracts
• Partner strategy and implementation lead
• External R&D

Who Should Sponsor?

 

• Platform Technology Providers
• Biotechs
• Big Pharma
• Consultants with expertise in vaccine development and execution
• Consultants on Legal affairs
• Consultants on Regulatory Affairs

 

Vaccine Partnerships Conference, Tuesday 16 April 2019

Barry Eisenstein
Vaccine Partnerships Conference
09:10

Can vaccines lessen the burden of antibiotic resistance?

-Who is CARB-X-What vaccines programs they are supporting -What they are looking for in a partner, public-private partnerships
Vaccine Partnerships Conference
09:30

FireChat 1 – FireChat 1 – Bacterial Vaccine

Gary Eldridge
Vaccine Partnerships Conference
09:45

FireChat 2 – Reducing Bacterial Adherence May Lessen Morbidity and Mortality caused by Urinary Tract Infections

Frank Malinoski
Vaccine Partnerships Conference
10:00

FireChat 3 – A combination, live attenuated, oral vaccine against Shigella and ETEC infections

10:40

Networking Coffee Break

Big pharmaceuticals Investing in novel platforms & viral vectors

Vaccine Partnerships Conference
11:40

FireChat 4 – DNA vaccine

Annette Vogel
Vaccine Partnerships Conference
11:55

FireChat 5 – Developing infectious disease vaccine using mRNA technologies for pharmacologically optimized protein coding RNA

Benjamin Petsch
Vaccine Partnerships Conference
12:10

FireChat 6 – Developing novel cancer immunotherapies based on optimized, antigen-encoding and complexed mRNA molecules

Boyd Clarke
Vaccine Partnerships Conference
12:25

FireChat 7 – A Single Intranasal Immunization with M2SR (M2 deletion, single replication) Vaccine Protects Against a Substantially Drifted H3N2 Influenza Virus in Human Challenge Study

13:10

Networking Lunch & Poster Session

David Noll
Vaccine Partnerships Conference
14:40

Strategies for Effective Partnerships with the US Government, NGOs, International Collaborators and Beyond.

Panel discussion
Vaccine Partnerships Conference
15:40

Successful case study 1: Sanofi – Translate Bio collaboration to develop mRNA vaccines for multiple infectious diseases

-How both companies identified the initial match?-How the responsibilities of each party were determined-Lessons learned so far and what both parties hope to achieve
16:09

Networking Coffee Break

Panel discussion
18:10

Chair’s Closing Remarks per co-lo and Close of Congress Day 2

18:15

Off-site Networking Drinks, Supported by Enesi Pharma

last published: 25/Mar/19 10:45

Vaccine Partnerships Conference, Wednesday 17 April 2019

Robin Nandy
Vaccine Partnerships Conference
09:25

UNICEF – An update on vaccine procurement and global immunization strategy

Michael Makanga
Vaccine Partnerships Conference
09:40

EDCTP – Public-Private partnership between Europe and sub-Saharan Africa to accelerate the development of vaccines

Melinda Wharton
Vaccine Partnerships Conference
09:55

NVPO – Priorities and how to improve vaccination system in the US, Adult Immunization, Vaccine Safety

Melinda Wharton, Director, Imm Svcs Division, CDC
Kimberly Thompson
Vaccine Partnerships Conference
10:10

NVAC – National Vaccine Plan Strategy, Topics affecting Vaccine Enterprise

10:40

Networking Coffee Break

12:30

Networking Lunch & Poster Session

DAY 3 AFTERNOON PLENARY OF CONGRESS: RENAISSANCE BALLROOM

Paul Offit
13:40

New lessons from old controversies

  • What have we learnt from previous vaccines failures to drive new vaccines forward?
  • Why is there is low uptake on currently available vaccines? E.g. HPV & influenza
  • Examples and case studies from: Lyme & Rota – what does this mean for future vaccine innovation and R&D?
Dr Saad Omer
14:55

A framework for a comprehensive maternal immunization platform

  • Evidence for current immunization recommendations
  • Maternal vaccines in development
  • The need for evidence-based interventions at the practice, provider, and patient levels to ensure higher vaccination levels
Dr Timothy Cooke
16:00

Chair Closing Remarks and End of Congress

last published: 25/Mar/19 10:45

 

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071